CervoMed reported Q3 2026 results highlighting progress in its drug neflamapimod for dementia with Lewy bodies (DLB) and other brain disorders. Key data presentations and regulatory advances support a 100mg twice-daily dosing regimen, with upcoming Phase 2a and Phase 2b trial results expected in late 2026 and early 2027. The company aims to partner for Phase 3 trials in DLB and advance studies in frontotemporal dementia, stroke recovery, and ALS. With $19.6 million cash on hand, CervoMed plans to fund operations through Q3 2027 while targeting transformative therapies for neurodegenerative diseases.
CervoMed's Q3 2026 results and updates provide context for readers. For those tracking health stocks, 108 of 150 US health-sector stocks rose, 26 fell as of Nov 09, 2026 18:41 WIB. Notable movers include NUWE at USD 4.74 (+3.49%), CTXR at USD 0.54 (-2.98%), and HIMS at USD 25.29 (-2.73%).
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
